The emerging safety profile of JAK inhibitors in rheumatic disease (Q39157033)

9 September 2017

title

The emerging safety profile of JAK inhibitors in rheumatic disease. (English)

1 reference

9 September 2017

Kevin L Winthrop

1

1 reference

9 September 2017

language of work or name

English

0 references

publication date

2 March 2017

1 reference

Nature Reviews Rheumatology

9 September 2017

published in

1 reference

9 September 2017

volume

13

1 reference

9 September 2017

issue

4

1 reference

9 September 2017

page(s)

234-243

1 reference

A new modality for immunosuppression: targeting the JAK/STAT pathway

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Back to the future: oral targeted therapy for RA and other autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Jaks and STATs: biological implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Cytokine signaling modules in inflammatory responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

JAK and STAT signaling molecules in immunoregulation and immune-mediated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Progressive multifocal leukoencephalopathy associated with ruxolitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

A partial form of recessive STAT1 deficiency in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

JAKs and STATs in immunity, immunodeficiency, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Baricitinib in Patients with Refractory Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

2013 IDSA clinical practice guideline for vaccination of the immunocompromised host

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Long-term persistence of zoster vaccine efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2017.23

Update on recommendations for use of herpes zoster vaccine

31 March 2020

1 reference

12 December 2020

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases

1 reference

12 December 2020

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

1 reference

12 December 2020

Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2017.23

1 reference

9 September 2017

1 reference